Orlistat 60mg reduces visceral adipose tissue: A 24-week randomized, placebo-controlled, multicenter trial

Obesity

Volumn 19, Issue 9, 2011, Pages 1796-1803

  Smith, Steven R ^a   Stenlof, Kaj S ^b   Greenway, Frank L ^a   McHutchison, John ^c   Schwartz, Susan M ^d   B Dev, Vidhu ^d   Berk, Evan S ^d   Kapikian, Roxanne ^d  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TETRAHYDROLIPSTATIN; ANTIOBESITY AGENT; ENZYME INHIBITOR; LACTONE; TRIACYLGLYCEROL LIPASE;

ABDOMINAL INFECTION; ABDOMINAL OBESITY; ADULT; ARTICLE; BLURRED VISION; BODY COMPOSITION; BODY WEIGHT; CHOLECYSTECTOMY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYSTIC DUCT LEAK; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FAT CONTENT; FEMALE; GALLSTONE; GASTROINTESTINAL DISEASE; HEALTH PROGRAM; HUMAN; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIFESTYLE MODIFICATION; LIPID ANALYSIS; LITHOTRIPSY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROLITHIASIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; WAIST CIRCUMFERENCE; WEIGHT CHANGE; WEIGHT REDUCTION; BODY MASS; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; LIVER; LOW CALORY DIET; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MUSCLE; OBESITY; PATHOLOGY; RADIOGRAPHY; TIME;

ADIPOSITY; ADULT; ANTI-OBESITY AGENTS; BODY MASS INDEX; COMBINED MODALITY THERAPY; DIET, REDUCING; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; HUMANS; INTRA-ABDOMINAL FAT; LACTONES; LIPASE; LIVER; MALE; MIDDLE AGED; MUSCLES; OVERWEIGHT; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; WEIGHT LOSS;

EID: 80052160446     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2011.143     Document Type: Article

References (33)

1. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006;444:881-887. (Pubitemid 46024995)
2. Vega GL, Adams-Huet B, Peshock R et al. Influence of body fat content and distribution on variation in metabolic risk. J Clin Endocrinol Metab 2006;91:4459-4466. (Pubitemid 44833423)
3. Jensen MD. Role of body fat distribution and the metabolic complications of obesity. J Clin Endocrinol Metab 2008;93:S57-S63.
4. Kuk JL, Katzmarzyk PT, Nichaman MZ et al. Visceral fat is an independent predictor of all-cause mortality in men. Obesity (Silver Spring) 2006;14:336-341. (Pubitemid 46214766)
5. McMillan KP, Kuk JL, Church TS, Blair SN, Ross R. Independent associations between liver fat, visceral adipose tissue, and metabolic risk factors in men. Appl Physiol Nutr Metab 2007;32:265-272.
6. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007;56:1010-1013. (Pubitemid 46525079)
7. Unger RH. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 2003;144:5159-5165. (Pubitemid 37476041)
8. Nguyen-Duy TB, Nichaman MZ, Church TS, Blair SN, Ross R. Visceral fat and liver fat are independent predictors of metabolic risk factors in men. Am J Physiol Endocrinol Metab 2003;284:E1065-E1071. (Pubitemid 36617450)
9. Fabbrini E, Magkos F, Mohammed BS et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 2009;106:15430-15435.
10. Yim JE, Heshka S, Albu J et al. Intermuscular adipose tissue rivals visceral adipose tissue in independent associations with cardiovascular risk. Int J Obes (Lond) 2007;31:1400-1405. (Pubitemid 47339927)
11. Anderson JW, Schwartz SM, Hauptman J et al. Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial. Ann Pharmacother 2006;40: 1717-1723. (Pubitemid 44544866)
12. Anderson JW. Orlistat for the management of overweight individuals and obesity: a review of potential for the 60-mg, over-the-counter dosage. Expert Opin Pharmacother 2007;8:1733-1742. (Pubitemid 47288178)
13. Tiikkainen M, Bergholm R, Rissanen A et al. Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women. Am J Clin Nutr 2004;79: 22-30. (Pubitemid 41132058)
14. Thomas EL, Makwana A, Newbould R et al. Pragmatic study of orlistat 60 mg on abdominal Obesity. Eur J Clin Nutr 2011. (in press)
15. Bellido GD. Orlistat reduces the visceral adipose tissue according to the central obesity grade. Int J Obes 2007:S170
16. Rolls B and Barnett RA. Volumetrics: Feel Full on Fewer Calories. Harper Collins: New York, 1999.
17. Smith SR, Lovejoy JC, Greenway F et al. Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity. Metab Clin Exp 2001;50:425-435. (Pubitemid 32321951)
18. Goodpaster BH, Thaete FL, Kelley DE. Thigh adipose tissue distribution is associated with insulin resistance in obesity and in type 2 diabetes mellitus. Am J Clin Nutr 2000;71:885-892. (Pubitemid 30176569)
19. Napolitano A, Miller SR, Murgatroyd PR et al. Validation of a quantitative magnetic resonance method for measuring human body composition. Obesity (Silver Spring) 2008;16:191-198. (Pubitemid 351271971)
20. Gray DS, Bray GA, Gemayel N, Kaplan K. Effect of obesity on bioelectrical impedance. Am J Clin Nutr 1989;50:255-260. (Pubitemid 19208740)
21. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28: 412-419. (Pubitemid 15018832)
22. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237: E214-E223. (Pubitemid 9249478)
23. Smith SR, Zachwieja JJ. Visceral adipose tissue: a critical review of intervention strategies. Int J Obes Relat Metab Disord 1999;23: 329-335. (Pubitemid 29182389)
24. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000;9:160-167.
25. Rössner S, Sjöström L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000;8:49-61.
26. Karhunen L, Franssila-Kallunki A, Rissanen P et al. Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns. Int J Obes Relat Metab Disord 2000;24:1567-1572.
27. Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005;293:2873-2883. (Pubitemid 41029141)
28. Chaston TB, Dixon JB. Factors associated with percent change in visceral versus subcutaneous abdominal fat during weight loss: findings from a systematic review. Int J Obes (Lond) 2008;32:619-628. (Pubitemid 351536009)
29. Ruan XY, Gallagher D, Harris T et al. Estimating whole body intermuscular adipose tissue from single cross-sectional magnetic resonance images. J Appl Physiol 2007;102:748-754. (Pubitemid 46220907)
30. Fabbrini E, Conte C, Magkos F. Methods for assessing intrahepatic fat content and steatosis. Curr Opin Clin Nutr Metab Care 2009;12:474-481.
31. Schwenzer NF, Springer F, Schraml C et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009;51:433-445.
32. Stern SE, Williams K, Ferrannini E et al. Identification of individuals with insulin resistance using routine clinical measurements. Diabetes 2005;54:333-339.
33. Swe Myint K, Napolitano A, Miller SR et al. Quantitative magnetic resonance (QMR) for longitudinal evaluation of body composition changes with two dietary regimens. Obesity (Silver Spring) 2010;18: 391-396.